Navigation Links
IRIDEX Licenses the Exclusive Rights to Ophthalmology Products and Intellectual Property from Ocunetics, Inc.
Date:9/20/2011

MOUNTAIN VIEW, Calif., Sept. 20, 2011 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced that it has exclusively licensed the rights to all of the intellectual property of Ocunetics, Inc., a privately held company based in Alamo, California.  Ocunetics develops procedure-enabling medical devices that are intended to increase surgeons' efficiency, while improving case predictability for ophthalmic surgeries.  Further terms of the deal have not been disclosed.  

"This is a great example of technology and talent that fit our culture and match our strategic initiative of rapidly expanding our portfolio of consumable instruments across the ophthalmology spectrum," said Theodore A. Boutacoff, President and CEO of IRIDEX. "Ocunetics' co-founders Timothy Buckley and Kenneth Peartree will join IRIDEX as Vice President of Marketing, MIGS & Laser Systems and Vice President of Product Development, Consumables, respectively, and we are excited about their future contributions to IRIDEX."

Ocunetics' co-founder and cataract/glaucoma surgeon Dr. Steven Vold added, "IRIDEX will accelerate the development and commercialization of the transformative product line created by Ocunetics. These products have been designed to improve efficiencies in a wide range of ophthalmic surgeries."  

Mr. Boutacoff concluded, "The benefits to the organization resulting from the agreement and the people will be immediate and broad. The Ocunetics products are currently in development and are expected to begin commercialization under the IRIDEX brand within 18 months."

About Ocunetics, Inc.

Ocunetics, Inc. was founded in 2011 with the mission of bringing innovative procedure-enabling medical devices to market quickly.  Through close collaboration with leading physicians and physician-inventors, the Ocunetics' team focuses on medical dev
'/>"/>

SOURCE IRIDEX Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. IRIDEX Introduces New ENT Laser Delivery Devices at AAO-HNSF Annual Meeting
2. IRIDEX Introduces Modular Multi-Wavelength Laser Solution at the American Academy of Ophthalmology
3. IRIDEX Introduces IQ 532 Dual Port Green Laser System at the American Academy of Ophthalmology
4. Ruediger Naumann-Etienne Appointed to IRIDEX Board of Directors
5. IRIDEX Announces Fourth Quarter and Full Year 2009 Conference Call and Release Date
6. IRIDEX Reports Fourth Quarter and Full Year 2009 Financial Results
7. IRIDEX Announces First Quarter 2010 Conference Call and Release Date
8. IRIDEX Announces First Commercial Shipment of New IQ 532(TM) Laser Systems
9. IRIDEX Granted U.S. Patent for Adjustable Laser Probe for Eye Surgery
10. IRIDEX Announces Second Quarter 2010 Conference Call and Release Date
11. IRIDEX Announces Commercial Availability of New Adjustable & Intuitive EndoProbe® Device for Eye Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 2014 UBM Medica US announces that  ... to help oncologists and other clinicians gain a better ... of targeted therapies and immunotherapies, discusses some of the ... Every September, Blood Cancer Awareness Month ... about blood cancers—helping to increase survival rates and improve ...
(Date:9/19/2014)... 19, 2014  Pressure BioSciences, Inc. (OTCQB: PBIO) ... received and approved all parts required to build ... begun to manufacture the new PCT-based instrument system.  ... ready for shipment by mid-October and that additional ... a rate of about one per week thereafter.  ...
(Date:9/19/2014)... , Sept. 19, 2014  Over 200 runners ... Future to Benefit the Radiation Oncology Institute (ROI), hosted ... at Golden Gate Park in San Francisco.  ... Moore , CEO of Radiation Business Solutions, "but ... have raised over $70,000 for the ROI this year. ...
Breaking Medicine Technology:OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 2Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 3Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 2Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 3
... CHADDS FORD, Pa., Oct. 22 Endo Pharmaceuticals (Nasdaq: ... and Company 21st Annual Healthcare Conference on Tuesday, November 2, 2010, ... Endo, will review the company,s products and development programs. ... from Endo,s website at www.endo.com under the investors section. ...
... Pharmaxis (ASX: PXS) today announced significant results of pooled ... III trials of Bronchitol (inhaled mannitol) in people with ... presented for the first time at the North American ... addition, more results from the second trial (CF302) have ...
Cached Medicine Technology:Pharmaxis Announces Positive Combined Phase 3 Cystic Fibrosis Trial Results 2Pharmaxis Announces Positive Combined Phase 3 Cystic Fibrosis Trial Results 3Pharmaxis Announces Positive Combined Phase 3 Cystic Fibrosis Trial Results 4Pharmaxis Announces Positive Combined Phase 3 Cystic Fibrosis Trial Results 5
(Date:9/22/2014)... CA (PRWEB) September 22, 2014 ... course from Winter & Alvin has just been ... excitement throughout the personal development community. The media ... attention of HonestyFirstReviews.com's Tiffany Hendricks prompting an investigative ... topic of great interest for many entrepreneurs and ...
(Date:9/22/2014)... 22, 2014 QueenBeeTickets.com has the largest ... larger with discount Stevie Wonder tickets. The phenomenal singer/songwriter ... Tour,” and 11 cities have been put on the ... , Click Here to view the selection ... , Stevie Wonder ticket sales are bound to be ...
(Date:9/22/2014)... AttorneyOne.com, a recognized authority on law, update the ... on Twix . , Mars Chocolate North America announced ... Stand Up Pouch with specific code date are recalled due ... is that Twix Unwrapped Bites 7 oz. Stand Up Pouch ... writing them on the ingredient label. , In case ...
(Date:9/22/2014)... 2014 The Center for Health ... ERC as one of the NorthCoast 99 ... places to work for top talent. This award recognizes ... maintain great workplaces that support the attraction, retention and ... staffing and workforce, development and training, compensation and rewards, ...
(Date:9/22/2014)... The Ruby Report was launched by the ... Conference in Louisville, Kentucky. This release followed the May ... reception attended by 60 people from the local area. ... gained while conducting her research, what drove her to ... and what she believes companies can do to be ...
Breaking Medicine News(10 mins):Health News:"The Millionaire's Brain" - A Review Examining Winter & Alvin's Training Course Released 2Health News:Discount Stevie Wonder Tickets: QueenBeeTickets.com Delights Customers with Discounted Concert Tickets for Stevie Wonder’s 11-City Tour Set to Kick off in November 2Health News:Mars Chocolate North America Recalls Twix Bites: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:The Center for Health Affairs Named to 2014 NorthCoast 99 List 2Health News:The Center for Health Affairs Named to 2014 NorthCoast 99 List 3Health News:Ruby Report Book Launch Reveals Critical Insights on Gender Intelligence 2
... 10 Caliper Life Sciences, Inc. (Nasdaq: ... at the Cowen and Company 29th Annual Health ... on Tuesday, March 17 at 10:15 a.m. ET. ... will be providing an update on the company,s ...
... Report Finds Public Health Programs At Risk During Economic ... and the Robert Wood Johnson Foundation (RWJF) today released ... received less funding from the federal government than Northeastern ... for disease prevention programs, which can amount to millions ...
... Designed to Optimize Treatment of Patients with Coronary ... Abbott ( NYSE: ABT ) today announced ... a next-generation balloon dilatation catheter with high-pressure capability ... coronary artery disease (CAD) during angioplasty procedures. VOYAGER ...
... 10 Johnson & Johnson will participate in the ... Monday, March 16th at the Boston Marriott Copley Place ... President, Finance and Chief Financial Officer, will represent the ... Time). The webcast will be available to investors and ...
... 10 The Kavli Foundation has announced the appointment ... - only the second president since the Foundation was ... Foundation,s President in late April of this year.Dr. Conn ... acclaimed scientist whose research is focused on plasma physics ...
... in the March issue of the Journal of ... transplantation should be used with caution in patients older ... with high rates of mortality after one year in ... the gold-standard treatment for a variety of end-stage lung ...
Cached Medicine News:Health News:Midwestern and Southern States Receive Least Federal Funding for Disease Prevention 2Health News:Midwestern and Southern States Receive Least Federal Funding for Disease Prevention 3Health News:Midwestern and Southern States Receive Least Federal Funding for Disease Prevention 4Health News:Abbott Launches VOYAGER(TM) NC Coronary Balloon Catheter 2Health News:Abbott Launches VOYAGER(TM) NC Coronary Balloon Catheter 3Health News:Abbott Launches VOYAGER(TM) NC Coronary Balloon Catheter 4Health News:Abbott Launches VOYAGER(TM) NC Coronary Balloon Catheter 5Health News:Dr. Robert W. Conn Named President of The Kavli Foundation 2Health News:Dr. Robert W. Conn Named President of The Kavli Foundation 3Health News:Dr. Robert W. Conn Named President of The Kavli Foundation 4Health News:Journal of American College of Surgeons finds lung transplantation should be used in older patients 2
... enzyme immunoassay kit for the quantitative ... in serum. Enzyme immunoassay (EIA) permits ... protein hormones in body fluids and ... and specific assay. This enzyme immunoassay ...
SHIONORIA BNP,is a reagent used in the measurement of blood BNP. The blood BNP test allows accurate estimation of coronary functions....
... immunosorbent assay method for the semi-quantitative ... myeloperoxidase in human serum. The results ... used as an aid in the ... conditions associated with elevated anti-neutrophil cytoplasmic ...
... The determination of Ang II ... monitoring the pharmacological effect and ... of angiotensin converting enzyme inhibitors ... receptor antagonists as well as ...
Medicine Products: